血浆输注的现状与展望*

doi:10.3969/j.issn.1671-2587.2024.02.005

临床输血与检验 ›› 2024, Vol. 26 ›› Issue (2): 180-186.DOI: 10.3969/j.issn.1671-2587.2024.02.005

血浆输注的现状与展望^*

刘睿宁, 汪德清

中国人民解放军总医院第一医学中心输血医学科,北京 100853

收稿日期:2024-02-07 出版日期:2024-04-20 发布日期:2024-04-23
通讯作者: 汪德清,主要从事临床输血风险控制研究,（E-mail）deqingw@vip.sina.com。
作者简介:刘睿宁,主要从事临床输血风险控制研究,（E-mail）liurn122@163.com。
基金资助:
*本课题受“十三五”全军后勤科研重点项目“战时血液安全保障关键技术研究”（No.BWS16J006）资助

Current Realities and Novel Improvements of Plasma Transfusion

LIU Ruining, WANG Deqing

Department of Transfusion Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing 100853

Received:2024-02-07 Online:2024-04-20 Published:2024-04-23

摘要/Abstract

摘要： 血浆作为临床常用的血液成分之一,已广泛应用于补充凝血因子,预防或治疗凝血因子缺乏引起的出血或出血倾向。虽然合理、科学用血理念已推行多年,但临床血浆输注仍存在诸多问题,如何科学精准输注血浆是目前亟待解决的问题。本文基于国内外输血指南及已发表的相关临床研究,就血浆输注的现状、应用与挑战进行综述,展望其未来发展方向,为推动输血医学治疗技术的发展提供参考。

关键词: 血浆输注, 血液管理, 输血不良反应

Abstract: Plasma, as the common blood components, has been widely used to supplement coagulation factors, which can prevent or treat bleeding or bleeding tendency caused by coagulation factor deficiency. Although the concept of rational and scientific transfusion has been implemented for many years, the majority of plasma transfusions are still sub-optimal, and achieving optimal plasma utilization is an ongoing challenge. Based on the domestic and international blood transfusion guidelines and published relevant clinical studies, this article reviews the current status, applications and challenges of plasma transfusion, looks forward to the future development, and update and expand the existing guidelines.

Key words: Plasma transfusion, Blood management, Adverse transfusion reaction

中图分类号:

R457

刘睿宁, 汪德清. 血浆输注的现状与展望^*[J]. 临床输血与检验, 2024, 26(2): 180-186.

LIU Ruining, WANG Deqing. Current Realities and Novel Improvements of Plasma Transfusion[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(2): 180-186.

参考文献

[1] LEISSINGER C.Another victory for patients with hemophilia[J].N Engl J Med,2023,388(4):372-373.
[2] 樊凤艳,汪德清.我国临床输血发展的挑战与思考[J].临床输血与检验,2021,23(1):10-12.
[3] 何欢,阙文君,余泽波.血浆输注的临床应用及管理研究进展[J].重庆医学,2023,52(12):1898-1902.
[4] DRAKE R,JACKSON B P,MURPHY C H.Single plasma unit transfusions in adults are either unnecessary or underdosed[J].Am J Clin Pathol,2022,158(1):148-152.
[5] GOEL R,CHAPPIDI M R,PATEL E U,et al.Trends in red blood cell,plasma,and platelet transfusions in the United States,1993-2014[J].JAMA,2018,319(8):825-827.
[6] 中华人民共和国国家卫生健康委员会.全血和成分血使用[S].2018.
[7] 周吉成,于洋,夏荣,等.输血相关急性肺损伤诊治中国专家共识(2023版)[J].临床输血与检验,2023,25(5):577-585.
[8] BISCOPING J.Therapy with blood components and plasma derivatives:the current cross-sectional guidelines[J].Anaesthesist,2009,58(11):1083-1084.
[9] HO A M H,DION P W,YEUNG J H H,et al.Prevalence of survivor bias in observational studies on fresh frozen plasma:erythrocyte ratios in trauma requiring massive transfusion[J].Anesthesiology,2012,116(3):716-728.
[10] MITRA B,JORGENSEN M,READE M C,et al.Patient blood management guideline for adults with critical bleeding[J]. Med J Aust,2024,220(4):211-216.
[11] GREEN L,BOLTON-MAGGS P,BEATTIE C,et al.British Society of Haematology Guidelines on the spectrum of fresh frozen plasma and cryoprecipitate products:their handling and use in various patient groups in the absence of major bleeding (Br J Haematol.2018;181:54-67).Addendum August 2020[J].Br J Haematol,2020,191(5):728-729.
[12] KUJOVICH J L.Hemostatic defects in end stage liver disease[J].Crit Care Clin,2005,21(3):563-587.
[13] VLAAR A P J,DIONNE J C,DE BRUIN S,et al.Transfusion strategies in bleeding critically ill adults:a clinical practice guideline from the European Society of Intensive Care Medicine[J].Intensive Care Med,2021,47(12):1368-1392.
[14] ROBACK J D,CALDWELL S,CARSON J,et al.Evidence-based practice guidelines for plasma transfusion[J].Transfusion,2010,50(6):1227-1239.
[15] O'SHAUGHNESSY D F,ATTERBURY C,BOLTON MAGGS P,et al.Guidelines for the use of fresh-frozen plasma,cryoprecipitate and cryosupernatant[J].Br J Haematol,2004,126(1):11-28.
[16] XU G P,WU L F,XU X M,et al.Information technology improves the quality of transfusion practice in China[J].Vox Sang,2023,118(2):138-146.
[17] ZHU C T,GAO Y L,LI Z Q,et al.A systematic review and meta-analysis of the clinical appropriateness of blood transfusion in China[J].Medicine (Baltimore),2015,94(50):e2164.
[18] 聂志扬,赵学彬,马婉茹,等.2020年全国临床用血质量控制指标调研分析[J].临床输血与检验,2023,25(4):514-517.
[19] HSU L I,CHEN J W,LIN D T,et al.The continued decline of plasma transfusions in Taiwan:an 11-year population-based study[J].Vox Sang,2022,117(4):535-544.
[20] BEVERINA I,NOVELLI C,GATTI A,et al.Efficacy of a strict surveillance policy towards inappropriateness of plasma transfusion[J].Transfus Apher Sci, 2019,58(4):423-428.
[21] SEHEULT J N,SHAZ B,BRAVO M,et al.Changes in plasma unit distributions to hospitals over a 10-year period[J].Transfusion,2018,58(4):1012-1020.
[22] QIANG J K,THOMPSON T,CALLUM J,et al.Variations in RBC and frozen plasma utilization rates across 62 Ontario community hospitals[J].Transfusion,2019,59(2):545-554.
[23] KHANDELWAL A,MINUK L,LIU Y,et al.Plasma transfusion practices:a multicentre electronic audit[J].Vox Sang,2022,117(10):1211-1219.
[24] ELLINGSON K D,SAPIANO M R P,HAASS K A,et al.Continued decline in blood collection and transfusion in the United States-2015[J].Transfusion,2017,57(S2):1588-1598.
[25] LU W.A concise synopsis of current literature and guidelines on the practice of plasma transfusion[J].Clin Lab Med,2021,41(4):635-645.
[26] DAVENPORT P,SOLA-VISNER M.Hemostatic challenges in neonates[J].Front Pediatr,2021,9:627715.
[27] FERRADA P,JACOBS L M.“Resuscitation of the exsanguinating trauma patient:Prioritize circulation and stop the bleed”[J]. Am J Surg,2023,226(2):294-295.
[28] TUCKER H,BROHI K,TAN J,et al.Association of red blood cells and plasma transfusion versus red blood cell transfusion only with survival for treatment of major traumatic hemorrhage in prehospital setting in England:a multicenter study[J]. Crit Care,2023,27(1):25.
[29] HOLCOMB J B,TILLEY B C,BARANIUK S,et al.Transfusion of plasma,platelets,and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma:the PROPPR randomized clinical trial[J]. JAMA,2015,313(5):471-482.
[30] BORGMAN M A,SPINELLA P C,PERKINS J G,et al.The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital[J]. J Trauma,2007,63(4):805-813.
[31] SHAYLOR R,WEINIGER C F,AUSTIN N,et al.National and international guidelines for patient blood management in obstetrics:a qualitative review[J]. Anesth Analg,2017,124(1):216-232.
[32] ARNI D,WILDHABER B E,MCLIN V,et al.Effects of plasma transfusions on antithrombin levels after paediatric liver transplantation[J]. Vox Sang,2018,113(6):569-576.
[33] PARKER J E,MARTINEZ A,DEUTSCH G K,et al.Safety of plasma infusions in Parkinson’s disease[J]. Mov Disord,2020,35(11):1905-1913.
[34] HANNESTAD J,DUCLOS T,CHAO W,et al.Safety and tolerability of GRF6019 infusions in severe Alzheimer’s disease:a phase II double-blind placebo-controlled trial[J]. J Alzheimers Dis,2021,81(4):1649-1662.
[35] DANI C,POGGI C,BRESCI C,et al.Early fresh-frozen plasma transfusion decreases the risk of retinopathy of prematurity[J]. Transfusion,2014,54(4):1002-1007.
[36] BAUER P R,OSTERMANN M,RUSSELL L,et al.Plasma exchange in the intensive care unit:a narrative review[J]. Intensive Care Med,2022,48(10):1382-1396.
[37] CERVANTES C E,BLOCH E M,SPERATI C J.Therapeutic plasma exchange:core curriculum 2023[J]. Am J Kidney Dis,2023,81(4):475-492.
[38] JR V V M. Acquired autoimmune thrombotic thrombocytopenic purpura[J]. Nursing,2019,49(1):22-29.
[39] EPSTEIN M A,SLADKY J T.The role of plasmapheresis in childhood Guillain-Barré syndrome[J]. Ann Neurol,1990,28(1):65-69.
[40] CLARK W F,HUANG S H S,WALSH M W,et al. Plasmapheresis for the treatment of kidney diseases[J]. Kidney Int,2016,90(5):974-984.
[41] SEXTON D J.Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis[J]. N Engl J Med,2020,382(22):2168.
[42] XING Y D,WANG S Q,LIU C Y,et al.Efficacy and safety of dual filtration plasmapheresis combined with biological agents in active refractory rheumatod arthritis[J].Medicine,2020,99(28):e20966.
[43] ZHANG F,ZHANG B Y,FAN R,et al.Clinical efficacy of plasma exchange in systemic lupus erythematosus during pregnancy[J].Immunity Inflam & Disease,2023,11(10): e1041.
[44] TIAN X,KONG Y J,WANG J,et al.Development of the Chinese Haemovigilance Network and reporting of adverse transfusion reactions from 2018 to 2020[J]. Vox Sang,2022,117(8):1027-1034.
[45] VAN DEN BRINK D P,KLEINVELD D J B,SLOOS P H,et al. Plasma as a resuscitation fluid for volume-depleted shock:potential benefits and risks[J]. Transfusion,2021,61(Suppl 1):S301-S312.
[46] GÖRLINGER K,SANER F H. Prophylactic plasma and platelet transfusion in the critically Ill patient:just useless and expensive or even harmful?[J]. BMC Anesthesiol,2015,15:86.
[47] CLIFFORD L,JIA Q,SUBRAMANIAN A,et al.Characterizing the epidemiology of postoperative transfusion-related acute lung injury[J]. Anesthes-iology,2015,122(1):12-20.
[48] KLANDERMAN R B,VAN MOURIK N,EGGERMONT D,et al.Incidence of transfusion-related acute lung injury temporally associated with solvent/detergent plasma use in the ICU:a retrospective before and after implementation study[J]. Transfusion,2022,62(9):1752-1762.
[49] OLSEN G,PASSWATER M,HUGGINS M,et al.Evaluation of A plasma for incompatible patients[J]. Transfusion,2021,61(2):375-378.
[50] ADAM E H,FISCHER D.Plasma transfusion practice in adult surgical patients:systematic review of the literature[J]. Transfus Med Hemother,2020,47(5):347-359.
[51] BOSBOOM J J,KLANDERMAN R B,ZIJP M,et al.Incidence,risk factors,and outcome of transfusion-associated circulatory overload in a mixed intensive care unit population:a nested case-control study[J]. Transfusion,2018,58(2):498-506.
[52] THALJI L,THUM D,WEISTER T J,et al.Incidence and epidemiology of perioperative transfusion-related pulmonary complications in pediatric noncardiac surgical patients:a single-center,5-year experience[J].Anesth Analg,2018,127(5):1180-1188.
[53] TUNG J P,CHIARETTI S,DEAN M M,et al.Trans-fusion-related acute lung injury (TRALI):potential pathways of development,strategies for prevention and treatment,and future research directions[J]. Blood Rev,2022,53:100926.
[54] KLANDERMAN R B,BULLE E B,HEIJNEN J W M,et al. Reported transfusion-related acute lung injury associated with solvent/detergent plasma - A case series[J]. Transfusion,2022,62(3):594-599.
[55] GILSTAD C W.Anaphylactic transfusion reactions[J]. Curr Opin Hematol,2003,10(6):419-423.
[56] MERDJI H,CLERE-JEHL R,MONNIER A,et al.Yellow urticaria following plasma transfusion[J]. Intensive Care Med,2018,44(1):100-101.
[57] SARANI B,DUNKMAN W J,DEAN L,et al.Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection[J]. Crit Care Med,2008,36(4):1114-1118.
[58] MCVEY M J,KAPUR R,CSERTI-GAZDEWICH C,et al.Transfusion-related acute lung injury in the periop erative patient[J]. Anesthesiology,2019,131(3): 693-715.
[59] JIA Q,BROWN M J,CLIFFORD L,et al.Prophylactic plasma transfusion for surgical patients with abnormal preoperative coagulation tests:a single-institution propensity-adjusted cohort study[J]. Lancet Haematol,2016,3(3):e139-e148.
[60] SOKOU R,PARASTATIDOU S,KONSTANTINIDI A,et al.Fresh frozen plasma transfusion in the neonatal population:a systematic review[J].Blood Rev,2022,55:100951.
[61] VIGNOLI A,TENORI L,MORSIANI C,et al.Serum or plasma (and which plasma),that is the question[J]. J Proteome Res,2022,21(4):1061-1072.

血浆输注的现状与展望^*

Current Realities and Novel Improvements of Plasma Transfusion

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

关于本刊

作者中心

在线期刊

访问统计

联系我们

[1]	陈岩, 陈麟凤, 何欣, 王岩, 于文娟, 刘璇, 刘思琪. 结直肠癌贫血患者围手术期用血影响因素分析: 一项单中心2013—2020年数据[J]. 临床输血与检验, 2024, 26(1): 79-85.
[2]	陈珊, 刘景福, 李珍, 陈玉娟, 叶先仁. 食管癌围手术期患者输血预测模型的建立^*[J]. 临床输血与检验, 2023, 25(6): 743-748.
[3]	耿凌云, 李景琦. 儿科患者血液管理的挑战与思考[J]. 临床输血与检验, 2023, 25(4): 439-443.
[4]	高原, 高旭蓉, 高洁, 纪宏文. 冠状动脉旁路移植术患者围术期贫血防治的研究进展^*[J]. 临床输血与检验, 2023, 25(4): 555-558.
[5]	郭天虹, 王雨涵, Claudia SC, 黄远帅. 基于研究证据的输血医学新进展[J]. 临床输血与检验, 2023, 25(4): 572-576.
[6]	黎欢, 谢佳, 何洪伟, 彭涛, 张利, 谭强, 胡燕, 吴玲. 心脏外科围术期大量输血患者输血相关呼吸系统不良反应回顾性调查[J]. 临床输血与检验, 2023, 25(3): 358-362.
[7]	李宜文, 余岚静子, 陶雨琦, 汪沁, 唐宗生. FFP输注对新生儿血凝指标的影响及临床意义^*[J]. 临床输血与检验, 2023, 25(3): 383-387.
[8]	中国输血协会免疫血液学专业委员会. 输血依赖型地中海贫血（TDT）患者临床输血中国专家共识[J]. 临床输血与检验, 2023, 25(2): 163-169.
[9]	黄蓉, 张宁洁, 郝珂, 郭天虹, 黄雪原, 谷兰, 傅云峰, 黄远帅, 王勇军, 陈秉宇, 周岚, 桂嵘. 从《AABB技术手册》（18版-20版）看国际输血技术新走向^*[J]. 临床输血与检验, 2023, 25(2): 170-179.
[10]	谢东甫, 黄霞, 杨俊鸿, 孙洁, 张晰, 何涛. 国内外血液安全监测报告若干数据指标的比较与分析^*[J]. 临床输血与检验, 2023, 25(1): 16-20.
[11]	王胜蓝, 贵明飞, 华敏玉, 李鹏, 卓创近, 刘钟梅, 杨霞, 黄霞, 何涛. 急性输血不良反应发生时间调查及分析^*[J]. 临床输血与检验, 2023, 25(1): 33-37.
[12]	周姗姗, 荆亚楠, 侯晓燕, 薛亚飞, 张媛媛, 黄霞, 王敏. 某三甲医院2021~2022年276例输血不良反应回顾性分析^*[J]. 临床输血与检验, 2023, 25(1): 38-43.
[13]	中国输血协会临床输血学专业委员会. 非心脏外科围手术期患者血液管理专家共识（2022版）[J]. 临床输血与检验, 2022, 24(5): 545-553.
[14]	陈学军, 徐军, 尹明伟, 周超, 沈月芳. 英格兰临床和实验室输血五年计划：输血2024的要点及启示[J]. 临床输血与检验, 2022, 24(5): 560-564.
[15]	胡婷婷, 王诗铭, 王希文, 海艳秋, 孙婷. 肿瘤患者输注血小板发生不良反应影响因素分析[J]. 临床输血与检验, 2021, 23(4): 464-468.